Oxalate-enriched diet activates IL-17A in mice, driving systemic inflammation and cardiac dysfunction

Researchers fed mice an oxalate-enriched diet and tracked immune activation via flow cytometry and cytokine assays alongside echocardiography for cardiac output. They observed elevated IL-17A, mitochondrial dysfunction in T cells, interstitial fibrosis, and a 25-30 percent drop in ejection fraction. Parallel measurements in primary hyperoxaluria patients confirmed higher circulating IL-17A, extending the mouse finding to a rare human condition with extreme oxalate load.

The work reframes oxalate beyond crystal nephrolithiasis. Prior large CKD cohorts already linked plasma oxalate to cardiovascular events, yet mechanistic bridges were missing. This study supplies one via IL-17A, a cytokine already targeted in psoriasis and now shown to worsen cardiorenal fibrosis when chronically elevated by dietary or metabolic oxalate.

Blocking IL-17A improved renal function, reduced fibrosis scores, and partially restored cardiac performance, suggesting a tractable axis. However, the model used supraphysiologic oxalate and short-term exposure, leaving dose-response and chronicity questions open for human translation.

Next steps include prospective oxalate and IL-17A measurement in CKD registries to test whether levels above 20-30 µmol/L predict incident heart failure independent of eGFR, followed by early-phase trials of IL-17A inhibitors in hyperoxaluric subgroups.